Benzinga's Top Pre-Market Gainers
Cyclacel Pharmaceuticals (NASDAQ: CYCC) soared 6.98% to $6.90 in the pre-market trading. Cyclacel Pharmaceuticals announced updated survival data from the pilot study and lead-in phase of SEAMLESS Phase 3 study.
Celldex Therapeutics (NASDAQ: CLDX) added 6.88% to $5.90 in the pre-market session. Celldex Therapeutics announced final results from the company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.
Ingersoll-Rand Plc (NYSE: IR) surged 2.28% to $49.80 in the pre-market session. Ingersoll-Rand announced its plans to spin off its security division.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.